CDSCO tells Sandoz to review and report PSUR data of Brolucizumab injection

Published On 2022-11-27 07:30 GMT | Update On 2022-11-27 07:30 GMT

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has recommended the drug maker Sandoz to review all the Periodic safety update reports (PSUR) data for Brolucizumab injection 120 mg/ml and present a summarized report of the PSUR data along with the Phase IV study report after completion of the study for further evaluation.

This came after the firm presented an interim safety analysis report of the ongoing Phase IV clinical trial for Brolucizumab injection 120 mg/ml as per the recommendation of the SEC Ophthalmology meeting held on November 5th, 2021.

The committee noted the results of the interim safety analysis of patients who have competed for one dosing of the drug.

In addition, the committee also noted that the firm has submitted three PSUR data to CDSCO up till and there was no additional safety signal identified as informed by the firm.

PSURs are pharmacovigilance documents intended to provide an evaluation of the risk-benefit balance of a medicinal product at defined time points after its authorisation. The objective of the PSUR is to present a comprehensive and critical analysis of the risk-benefit balance of the product, taking into account new or emerging safety information in the context of cumulative information on risk and benefits.

Brolucizumab is a monoclonal antibody indicated to treat neovascular age-related macular degeneration. Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor that targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduces the proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.

At the recent SEC meeting for Ophthalmology held on 28th October 2022, the expert panel reviewed the interim safety analysis report of the ongoing Phase IV clinical trial of the Ophthalmic drug Brolucizumab injection 120 mg/ml

After detailed deliberation, the committee opined that the firm should review all the PSUR data of the drug and present a summarized report of the PSUR data along with the Phase IV study report after the completion of the study for further evaluation by the committee.

Also Read:Eli Lilly Gets CDSCO Nod To Study Anti-diabetic Dulaglutide

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO tells Sandoz to review and report PSUR data of Brolucizumab injection

Similar News

AstraZeneca's Proposal to Increase Sample Size in Zibotentan-Dapagliflozin Global Trial Gets SEC Nod

Govt Allows Stickering, Orders New MRPs Post GST Reduction, AiMeD Welcomes Directive

Sun Pharma Secures Interim Court Relief In URSOCOL Trademark Dispute

Nellore Horror: 21-year-old B.Pharm student stabbed to death

Upcoming Una Bulk Drug Park receives environmental clearance

CDSCO Panel Nod To Phase I Clinical Trial of Anticancer Drug Bevacizumab by Jeevan Scientific

Orissa HC Seeks Govt Roadmap on Advanced Blood Testing Technology

AstraZeneca Faces NPPA Heat Over Symbicort Pricing, Slapped Rs 60 Crore Showcause Notice